tiprankstipranks
Trending News
More News >
Resmed (RMD)
NYSE:RMD
US Market
Advertisement

Resmed (RMD) Stock Forecast & Price Target

Compare
1,128 Followers
See the Price Targets and Ratings of:

RMD Analyst Ratings

Strong Buy
13Ratings
Strong Buy
10 Buy
3 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$304.10
▲(7.35% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $304.10 with a high forecast of $330.00 and a low forecast of $270.00. The average price target represents a 7.35% change from the last price of $283.28.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"220":"$220","331":"$331","247.75":"$247.8","275.5":"$275.5","303.25":"$303.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":330,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$330.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":304.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$304.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$270.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[220,247.75,275.5,303.25,331],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,270.85,275.40000000000003,279.95000000000005,284.5,289.05,293.6,298.15000000000003,302.7,307.25,311.8,316.35,320.9,325.45,{"y":330,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,270.85,273.40769230769234,275.96538461538466,278.5230769230769,281.08076923076925,283.63846153846157,286.1961538461539,288.75384615384615,291.3115384615385,293.8692307692308,296.4269230769231,298.9846153846154,301.5423076923077,{"y":304.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,270.85,270.7846153846154,270.71923076923076,270.6538461538462,270.58846153846156,270.5230769230769,270.4576923076923,270.3923076923077,270.3269230769231,270.26153846153846,270.19615384615383,270.13076923076926,270.06538461538463,{"y":270,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":236.69,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":227.21,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":221.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$330.00Average Price Target$304.10Lowest Price Target$270.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on RMD
TR | OpenAI - 4o
TR | OpenAI - 4o
$306$313
Buy
10.49%
Upside
Reiterated
10/01/25
AI Generated ArticleAI Generated Article
Citi
$330
Buy
16.49%
Upside
Reiterated
09/30/25
Resmed's Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura SutcliffeWe are in line for FY26 but above thereafter, with VA consensus flatlining below 63%. We think this ignores remaining mix shift to the AirSense 11 and management ambitions for annual gross margin improvement through 2030.
Bank of America Securities Analyst forecast on RMD
Bank of America Securities
Bank of America Securities
$300
Buy
5.90%
Upside
Reiterated
09/24/25
Resmed's Strategic Growth and Competitive Edge Support Buy Rating with $300 Price TargetWe hosted RMD London conference. Topics covered included WLD drugs impact, demand generation/capture, and margin expansion. We maintain our Buy rating given positive growth outlook. In particular, we appreciate RMD efforts to create and capture demand.
KeyBanc
$298
Buy
5.20%
Upside
Reiterated
09/17/25
KeyBanc Remains a Buy on Resmed (RMD)
UBS
$325
Buy
14.73%
Upside
Reiterated
09/16/25
UBS Keeps Their Buy Rating on Resmed (RMD)UBS reiterates Buy Rating on ResMed (RMD) Following GLP-1 Survey
William Blair Analyst forecast on RMD
William Blair
William Blair
Buy
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Envista Holdings (NYSE: NVST)
Stifel Nicolaus Analyst forecast on RMD
Stifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
Piper Sandler Analyst forecast on RMD
Piper Sandler
Piper Sandler
$270
Hold
-4.69%
Downside
Reiterated
08/01/25
Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)
Mizuho Securities Analyst forecast on RMD
Mizuho Securities
Mizuho Securities
$270$290
Buy
2.37%
Upside
Reiterated
08/01/25
ResMed price target raised to $290 from $270 at MizuhoResMed price target raised to $290 from $270 at Mizuho
J.P. Morgan Analyst forecast on RMD
J.P. Morgan
J.P. Morgan
$310
Buy
9.43%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO), Resmed (NYSE: RMD) and Envista Holdings (NYSE: NVST)
Robert W. Baird Analyst forecast on RMD
Robert W. Baird
Robert W. Baird
$283$305
Buy
7.67%
Upside
Reiterated
08/01/25
ResMed price target raised to $305 from $283 at BairdResMed price target raised to $305 from $283 at Baird
RBC Capital Analyst forecast on RMD
RBC Capital
RBC Capital
$294$300
Buy
5.90%
Upside
Reiterated
08/01/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch Health Companies (NYSE: BHC), Resmed (NYSE: RMD) and Biogen (NASDAQ: BIIB)
Needham
Hold
Reiterated
08/01/25
Needham Reaffirms Their Hold Rating on Resmed (RMD)
Morgan Stanley Analyst forecast on RMD
Morgan Stanley
Morgan Stanley
$280$286
Buy
0.96%
Upside
Reiterated
05/20/25
Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities
Jefferies Analyst forecast on RMD
Unknown Analyst
Jefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on RMD.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on RMD
TR | OpenAI - 4o
TR | OpenAI - 4o
$306$313
Buy
10.49%
Upside
Reiterated
10/01/25
AI Generated ArticleAI Generated Article
Citi
$330
Buy
16.49%
Upside
Reiterated
09/30/25
Resmed's Strategic Positioning and Growth Prospects: A Buy Recommendation by Laura SutcliffeWe are in line for FY26 but above thereafter, with VA consensus flatlining below 63%. We think this ignores remaining mix shift to the AirSense 11 and management ambitions for annual gross margin improvement through 2030.
Bank of America Securities Analyst forecast on RMD
Bank of America Securities
Bank of America Securities
$300
Buy
5.90%
Upside
Reiterated
09/24/25
Resmed's Strategic Growth and Competitive Edge Support Buy Rating with $300 Price TargetWe hosted RMD London conference. Topics covered included WLD drugs impact, demand generation/capture, and margin expansion. We maintain our Buy rating given positive growth outlook. In particular, we appreciate RMD efforts to create and capture demand.
KeyBanc
$298
Buy
5.20%
Upside
Reiterated
09/17/25
KeyBanc Remains a Buy on Resmed (RMD)
UBS
$325
Buy
14.73%
Upside
Reiterated
09/16/25
UBS Keeps Their Buy Rating on Resmed (RMD)UBS reiterates Buy Rating on ResMed (RMD) Following GLP-1 Survey
William Blair Analyst forecast on RMD
William Blair
William Blair
Buy
Reiterated
08/27/25
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Envista Holdings (NYSE: NVST)
Stifel Nicolaus Analyst forecast on RMD
Stifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
08/13/25
We remain Hold‐rated on Resmed (RMD, $283.29, Hold) within our Sleep segment commentary.
Piper Sandler Analyst forecast on RMD
Piper Sandler
Piper Sandler
$270
Hold
-4.69%
Downside
Reiterated
08/01/25
Piper Sandler Reaffirms Their Hold Rating on Resmed (RMD)
Mizuho Securities Analyst forecast on RMD
Mizuho Securities
Mizuho Securities
$270$290
Buy
2.37%
Upside
Reiterated
08/01/25
ResMed price target raised to $290 from $270 at MizuhoResMed price target raised to $290 from $270 at Mizuho
J.P. Morgan Analyst forecast on RMD
J.P. Morgan
J.P. Morgan
$310
Buy
9.43%
Upside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO), Resmed (NYSE: RMD) and Envista Holdings (NYSE: NVST)
Robert W. Baird Analyst forecast on RMD
Robert W. Baird
Robert W. Baird
$283$305
Buy
7.67%
Upside
Reiterated
08/01/25
ResMed price target raised to $305 from $283 at BairdResMed price target raised to $305 from $283 at Baird
RBC Capital Analyst forecast on RMD
RBC Capital
RBC Capital
$294$300
Buy
5.90%
Upside
Reiterated
08/01/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch Health Companies (NYSE: BHC), Resmed (NYSE: RMD) and Biogen (NASDAQ: BIIB)
Needham
Hold
Reiterated
08/01/25
Needham Reaffirms Their Hold Rating on Resmed (RMD)
Morgan Stanley Analyst forecast on RMD
Morgan Stanley
Morgan Stanley
$280$286
Buy
0.96%
Upside
Reiterated
05/20/25
Resmed's Growth Potential Highlighted by Promising Trial Results and Future Opportunities
Jefferies Analyst forecast on RMD
Unknown Analyst
Jefferies
Not Ranked
Jefferies
Hold
Reiterated
05/02/25
We maintain our Hold rating on RMD.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

1 Month
xxx
Success Rate
13/21 ratings generated profit
62%
Average Return
+4.24%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +4.24% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
+4.83%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +4.83% per trade.
1 Year
Lyanne HarrisonBank of America Securities
Success Rate
20/25 ratings generated profit
80%
Average Return
+15.76%
reiterated a buy rating 15 days ago
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +15.76% per trade.
2 Years
xxx
Success Rate
22/25 ratings generated profit
88%
Average Return
+27.68%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.00% of your transactions generating a profit, with an average return of +27.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
18
11
20
28
22
Hold
7
2
4
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
13
24
32
26
In the current month, RMD has received 22 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 304.10.
Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $2.53 with a range of $2.45 to $2.62. The previous quarter’s EPS was $2.55. RMD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RMD has Preformed in-line its overall industry.
Next quarter’s earnings estimate for RMD is $2.53 with a range of $2.45 to $2.62. The previous quarter’s EPS was $2.55. RMD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RMD has Preformed in-line its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $1.33B with a range of $1.31B to $1.36B. The previous quarter’s sales results were $1.35B. RMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RMD has Preformed in-line its overall industry.
Next quarter’s sales forecast for RMD is $1.33B with a range of $1.31B to $1.36B. The previous quarter’s sales results were $1.35B. RMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RMD has Preformed in-line its overall industry.

RMD Stock Forecast FAQ

What is RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is 304.10.
    What is RMD’s upside potential, based on the analysts’ average price target?
    Resmed has 7.35% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RMD a Buy, Sell or Hold?
          Resmed has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Resmed’s price target?
            The average price target for Resmed is 304.10. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $330.00 ,the lowest forecast is $270.00. The average price target represents 7.35% Increase from the current price of $283.28.
              What do analysts say about Resmed?
              Resmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of RMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis